drugset / Trial / NCT00408655

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00408655

Phase 1 Completed 38 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of temsirolimus, carboplatin, and paclitaxel in treating patients with advanced solid tumors. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with chemotherapy may kill more tumor cells.

Timeline

Start
2007-02
Primary completion
2012-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Paclitaxel Small molecule Intravenous
Subject Temsirolimus Small molecule Intravenous